索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]张羽坤,张禹,胡兴丽,等.高尿酸血症与心房颤动[J].国际心血管病杂志,2021,01:22-24.
点击复制

高尿酸血症与心房颤动(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年01期
页码:
22-24
栏目:
综述
出版日期:
2021-01-20

文章信息/Info

Title:
-
作者:
张羽坤; 张禹; 胡兴丽; 李静; 赵昱
563003 遵义 贵州航天医院心血管内科
Author(s):
-
关键词:
高尿酸血症;  心房颤动;  血清尿酸
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.01.006
文献标识码:
-
摘要:
研究表明血清尿酸水平升高与心房颤动(房颤)的发生、维持和复发相关。高尿酸血症可能通过氧化应激、炎性反应、细胞内尿酸的聚集,导致心房电重构、机械重构,进而促进房颤发生。深入研究尿酸水平增高导致房颤发生发展的机制,探索抑制房颤发生的关键靶点,寻找合适的药物进行干预治疗具有重要意义
Abstract:
-

参考文献/References

[1] Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study[J]. Circulation, 2014, 129(8):837-847.
[2] Chen Y, Xia Y, Han X, et al. Association between serum uric acid and atrial fibrillation: a cross-sectional community-based study in China[J].BMJ Open, 2017, 7(12):e019037.
[3] Mantovani A, Rigolon R, Civettini A, et al. Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring[J].J Endocrinol Invest, 2018, 41(2):223-231.
[4] Kuwabara M, Niwa K, Nishihara S,et al. Hyperuricemia is an independent competing risk factor for atrial fibrillation[J].Int J Cardiol, 2017, 231:137-142.
[5] Valbusa F, Bertolini L, Bonapace S, et al. Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus[J].Am J Cardiol, 2013, 112(4):499-504.
[6] Liu T, Zhang X, Korantzopoulos P, et al. Uric acid levels and atrial fibrillation in hypertensive patients[J].Intern Med, 2011, 50(8):799.
[7] Pak S, Yatsynovich Y, Valencia D, et al. Serum uric acid and atrial fibrillation: meta-analysis[J].Crit Pathw Cardiol, 2018, 17(3):161-166.
[8] Korantzopoulos P, Kolettis TM, Galaris D, et al. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation[J].Int J Cardiol, 2007, 115:135-143.
[9] Doehner W, Landmesser U. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options[J].Semin Nephrol, 2011, 31:433-440.
[10] Glantzounis GK, Tsimoyiannis EC, Kappas AM, et al. Uric acid and oxidative stress[J].Curr Pharm Des, 2005, 11:4145-4151.
[11] Landmesser U, Spiekermann S, Preuss C, et al. Angiotensin ii induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease[J].Arterioscler Thromb Vasc Biol, 2007, 27:943-948.
[12] Letsas KP, Korantzzopoulos P, Filippatos GS, et al. Uric acid elevation in atrial fibrillation[J].Hellenic J Cardiol, 2010, 51(3):209-213.
[13] George J, Struthers AD. Role of urate, xanthine oxidase and the effects of allopurion in vascular oxidative stress[J].Vasc Health Risk Manag, 2009, 5(1):265.
[14] Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug[J].Cardiol Rev, 2011, 19(6):265.
[15] 姚艳, 赵婧华, 冯莉. 心房颤动合并脑栓塞患者血浆同型半胱氨酸的水平及其与CHA2DS2-VASc评分的关系[J]. 中国心脏起搏与心电生理杂志, 2015, 29(3):221.
[16] Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta analysis[J]. Arthritis Rheum, 2009, 61:885-892.
[17] Heo SH, Lee SH. High levels of serum uric acid are associated with silent brain infarction[J]. J Neurol Sci, 2010, 297:6-10.
[18] Chao TF, Liu CJ, Chen SJ, et al. Hyperuricemia and the risk of ischemic stroke in patients with atrial fibeillation-could it refine clinical risk stratification in AF?[J]. Int J Cardiol, 2014, 170:344-349.
[19] Numa S, Hirai T, Nakagawa K, et al. Hyperuricemia and transesophageal echocardio graphic thromboembolic risk in patients with atrial fibrillation at clinically low-intermediate risk[J]. Circ J, 2014, 78:1600-1605.
[20] Hernandez FE, Tamariz L, Hare J. Allopurinol decreases the incidence of atrial fibrillation in heart failure patients[J].J Am Coll Cardiol, 2013, 61(10):E409.
[21] Singh JA, Yu S. Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data[J].Ann Rheum Dis, 2016, 76(1):72-78.
[22] Stull LB, Leppo MK, Szweda L, et al. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy[J]. CireRes, 2004, 95(10):1005-1011.
[23] Sakabe M, Fujiki A, Sakamoto T, et al. Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction[J]. Cardiovasc Electrophysiol, 2012, 23(10):1130-1135.
[24] Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina:a randomised, placebo control ledcross overtrial[J]. Lancet, 2010, 375(9732):2161-2167.
[25] Rekhraj S, Gandy SJ, Szwe jkowski BR, et al. High-dose allopurinoleeduces left ventricular mass in patients with ischemic heart disease[J]. J Am Coll Cardiol, 2013, 61(9):926-932.
[26] Beattie CJ, Fulton RL, Higgins P, et al. Allopurinol initiation and change in blood pressure in older adults with hypertension[J]. Hypertension, 2014, 64(5):1102-1107.

备注/Memo

备注/Memo:
基金项目:遵义市科技联合基金[遵市科合HZ字(2019)221号]
更新日期/Last Update: 2021-01-20